Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13793493 | 0.77 | — | — | |
| SCHEMBL21164655 | 0.76 | FAAH (0.40) | KDM4ESMN1; SMN2MAPTTSHRCNR2 | |
| SCHEMBL2343053 | 0.74 | TSHR (0.58) | KDM4ESMN1; SMN2MAPTTSHRGAA | |
| SCHEMBL9965485 | 0.74 | SMN1; SMN2 (0.39) | SMN1; SMN2MAPTKDM1AHDAC2NPC1 | |
| SCHEMBL18181899 | 0.73 | FAAH (0.43) | KDM4ESMN1; SMN2MAPTTSHRFAAH | |
| SCHEMBL18867055 | 0.72 | LMNA (0.41) | SMN1; SMN2MAPTKDM1ATSHRHDAC2 | |
| SCHEMBL8375417 | 0.72 | ALDH1A1 (0.46) | SMN1; SMN2MAPTKDM1ATSHRHDAC2 | |
| SCHEMBL13354157 | 0.72 | — | — | |
| SCHEMBL12057388 | 0.71 | HDAC2 (0.41) | SMN1; SMN2MAPTTSHRHDAC2CNR2 | |
| SCHEMBL12669780 | 0.71 | SMN1; SMN2 (0.43) | SMN1; SMN2MAPTTSHRNPC1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | WASE, NISHIKANT | 2020-03-05 | — | — | US | disclosed |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | NUTECH VENTURES (US) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | FASN, LIPC, SREBF2 | KDM4E 1755/4885SMN1; SMN2 4517/4885MAPT 3197/4885 |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | KDM4E 1755/4885SMN1; SMN2 4517/4885MAPT 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.